ELIGARD 22.5mg clinical trials

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

This study looks at treating prostate cancer that has come back in a few spots. We're comparing targeted radiation or surgery with adding a hormone-blocking drug called ELIGARD® to see if it stops the cancer from growing for longer.